Welcome to our dedicated page for Select Medical SEC filings (Ticker: SEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Select Medical’s SEC documents rarely fit neatly into a single spreadsheet. Four business segments—critical illness recovery hospitals, rehabilitation hospitals, outpatient rehab clinics and Concentra occupational health centers—generate dozens of revenue streams, reimbursement rules and lease obligations. Hunting for segment margin shifts, payer-mix tables or insider trades inside a 300-page filing can stall decision-making. That’s why investors looking for Select Medical SEC filings explained simply start here.
Stock Titan’s AI decodes every disclosure the moment it hits EDGAR. Open a Select Medical quarterly earnings report 10-Q filing and our engine flags census trends and CMS updates in plain English. Need real-time alerts? We stream Select Medical Form 4 insider transactions real-time so you’ll never miss new Select Medical insider trading Form 4 transactions or spot patterns in Select Medical executive stock transactions Form 4. The platform also links each 8-K so you get Select Medical 8-K material events explained within minutes, plus a side-by-side view of the proxy for Select Medical proxy statement executive compensation details.
Whether you’re comparing hospital occupancy quarter-over-quarter or estimating clinic throughput, our AI-powered summaries pull the ratios, segment revenues and risk factors that matter. Tap into clear charts for Select Medical earnings report filing analysis, download the workbook that underpins every footnote, or bookmark the Select Medical annual report 10-K simplified to see historical trends. Understanding Select Medical SEC documents with AI means spending less time parsing legalese and more time acting on insights—all filings, all forms, updated in real time.
Select Medical Holdings (SEM): Executive Vice President John F. Duggan reported a Form 4 transaction on 11/01/2025. He surrendered 4,865 shares of common stock at $13.83 under code F to satisfy tax withholding related to the vesting of restricted stock.
Following this administrative withholding, he directly owns 194,710 shares. This filing reflects a tax-related share withholding rather than an open-market sale.
Select Medical Holdings (SEM)11/01/2025, the CFO executed a Code F transaction, surrendering 7,357 shares of common stock at $13.83 per share to cover tax withholding tied to the vesting of restricted stock.
Following this tax-related withholding, the CFO beneficially owns 238,057 shares on a direct basis. This filing reflects administrative share withholding rather than an open‑market sale.
Select Medical Holdings (SEM) reported an insider equity award. An Executive Vice President acquired 50,000 shares of common stock on 10/28/2025 at $0 per share, recorded as a grant of restricted stock. Following the transaction, the officer beneficially owns 199,575 shares, held directly.
The restricted stock, subject to certain exceptions, will vest in full on 10/28/2029, the fourth anniversary of the grant date.
Select Medical Holdings (SEM) reported an insider equity transaction. A director received 1,266 shares of common stock on 10/28/2025 at a price of $14.22 per share. Following the grant, the reporting person beneficially owned 304,063 shares, held directly.
The filing states this was a restricted stock grant under the 2020 Equity Incentive Plan, issued in lieu of a quarterly cash retainer of $18,000. This reflects routine director compensation in stock rather than cash.
Select Medical Holdings (SEM) reported an insider equity award. The company’s Chief Accounting Officer received a grant of 20,000 shares of restricted stock on 10/28/2025 at $0 per share. According to the terms, the award will vest in full on October 28, 2029. Following the grant, the reporting person beneficially owns 54,254 shares, held directly.
Select Medical Holdings Corporation furnished a press release announcing financial results for the third quarter ended September 30, 2025. The materials were provided under Item 2.02 and are treated as furnished, not filed, under the Exchange Act.
The Board also declared a cash dividend of $0.0625 per share, payable on or about November 25, 2025 to stockholders of record as of the close of business on November 12, 2025. The press release with financial schedules was included as Exhibit 99.1.
Select Medical Holdings (SEM) reported Q3 results with revenue of $1,363,445 thousand, up from $1,271,582 thousand a year ago. Income from continuing operations, net of tax, was $44,180 thousand versus $41,276 thousand, and EPS from continuing operations was $0.23 versus $0.19. Adjusted EBITDA reached $111,655 thousand compared with $103,898 thousand.
By segment, revenue was $609,929 thousand in Critical Illness Recovery Hospitals, $328,607 thousand in Rehabilitation Hospitals, and $325,383 thousand in Outpatient Rehabilitation. For the nine months ended September 30, 2025, revenue was $4,056,196 thousand and income from continuing operations, net of tax, was $176,791 thousand, with EPS from continuing operations of $1.00. Operating cash flow for the period was $282,142 thousand, and capital expenditures were $170,125 thousand. Total debt had a carrying value of $1,772,149 thousand. As of September 30, 2025, SEM had 123,817,591 shares outstanding.
John F. Duggan, Executive Vice President and a director of Select Medical Holdings Corporation (SEM), reported beneficial ownership of 149,575 shares of the issuer's common stock. The filing discloses four grants of restricted stock: three grants of 25,000 shares (granted on November 1 of 2021, 2022 and 2023) and one grant of 50,000 shares (granted April 30, 2024). Each grant includes vesting schedules that generally fully vest on the fourth anniversary of the grant date, with a special one‑third vesting event noted on November 5, 2024, and other customary exceptions.
Select Medical Holdings Corporation (SEM) filed an 8-K reporting leadership changes. The filing references Item 5.02 and Item 7.01 and includes an exhibit: a press release dated September 2, 2025 announcing the appointment of Mr. Mullin as Chief Executive Officer and noting other changes involving long-tenured leaders. The 8-K indicates the company furnished written communications under Regulation FD and provided the press release as Exhibit 99.1. The disclosure signals a formal CEO transition and related leadership adjustments, documented through the company’s required SEC communication channels.
FAQ
What is the current stock price of Select Medical (SEM)?
What is the market cap of Select Medical (SEM)?
